Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease

Clinical Transplantation

Volumn 28, Issue 12, 2014, Pages 1339-1348

  Thimonier, Elsa ^a   Guillaud, Olivier ^a   Walter, Thomas ^a,b   Decullier, Evelyne ^c   Vallin, Mélanie ^a   Boillot, Olivier ^a,b   Dumortier, Jérôme ^a,b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

Alcoholic liver disease; de novo carcinoma; Everolimus; Liver transplantation; Prognosis

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; METHYLPREDNISOLONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; METASTASIS; RETROSPECTIVE STUDY; RISK FACTOR; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FOLLOW UP; LIVER CIRRHOSIS, ALCOHOLIC; MIDDLE AGED; MORTALITY; NEOPLASMS; POSTOPERATIVE COMPLICATION; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; SURVIVAL RATE;

EID: 84919333192     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12430     Document Type: Article

References (34)

1. National Institutes of Health Consensus Development Conference on Liver Transplantation. Sponsored by the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases and the National Institutes of Health Office of Medical Applications of Research. Hepatology 1984: 1(Suppl): 1S.
2. Adam R, Karam V, Delvart V et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012: 57: 675.
3. Starzl TE, Van Thiel D, Tzakis AG et al. Orthotopic liver transplantation for alcoholic cirrhosis. JAMA 1988: 260: 2542.
4. Haagsma EB, Hagens VE, Schaapveld M et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001: 34: 84.
5. Aberg F, Pukkala E, Höckerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl 2008: 14: 1428.
6. Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010: 10: 1420.
7. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011: 306: 1891.
8. Herrero JI, Lorenzo M, Quiroga J et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005: 11: 89.
9. Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002: 8: 482.
10. Dumortier J, Guillaud O, Adham M et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007: 102: 1032.
11. Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009: 137: 2010.
12. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010: 30: 1247.
13. Faure S, Herrero A, Jung B et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol 2012: 57: 306.
14. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999: 397: 530.
15. Tjon ASW, SintNicolaas J, Kwekkeboom J et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010: 16: 837.
16. Seeliger H, Guba M, Kleespies A, Jauch K-W, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev 2007: 26: 611.
17. Mabuchi S, Altomare DA, Connolly DC et al. RAD001 (everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007: 67: 2408.
18. Wu Q, Kiguchi K, Kawamoto T et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 2007: 67: 3794.
19. Namba R, Young LJT, Abbey CK et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 2006: 12: 2613.
20. Gutiérrez-Dalmau A, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007: 22(Suppl 1): i11.
21. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
22. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
23. Gomez-Camarero J, Salcedo M, Rincon D et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 2007: 84: 786.
24. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005: 79: 855.
25. Végso G, Tóth M, Hídvégi M et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res 2007: 13: 63.
26. Vanlemmens C, Di Martino V, Milan C et al. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med 2009: 150: 153.
27. Maluccio M, Sharma V, Lagman M et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003: 76: 597.
28. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008: 372: 449.
29. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011: 364: 514.
30. Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012: 8: 651.
31. Levy G, Schmidli H, Punch J et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006: 12: 1640.
32. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005: 352: 1317.
33. Stippel DL, Kasper HU, Schleimer K et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005: 37: 2185.
34. Garcia VD, BonamigoFilho JL, Neumann J et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003: 16: 202.